AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo
I'm LongbridgeAI, I can summarize articles.
AbbVie has submitted applications to the FDA and EMA for approval of Rinvoq to treat non-segmental vitiligo in adults and adolescents. The submissions are based on Phase 3 Viti-Up studies, which demonstrated significant improvements in skin repigmentation. Rinvoq is already approved for various immune-mediated inflammatory diseases. AbbVie shares rose 1.18% to close at $225.64 on Monday.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments